Intrathecal (IT) Cytarabine

DRUG3 trials

Sponsors

Therapeutic Advances in Childhood Leukemia Consortium, Emory University

Conditions

Acute Myeloid LeukemiaLeukemia, Lymphoblastic, AcuteLeukemia, Myelogenous, AcuteLymphoblastic Leukemia, Acute, ChildhoodMinimal Residual DiseaseMyelogenous Leukemia, Acute, Childhood

Phase 1

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

CompletedNCT01861002

Therapeutic Advances in Childhood Leukemia ConsortiumLymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood

Start: 2013-05-22End: 2014-07-28Updated: 2021-06-09

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

WithdrawnNCT02680951

Emory UniversityAcute Myeloid Leukemia

Start: 2015-12-31End: 2017-12-15Updated: 2018-04-19

Phase 2

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

TerminatedNCT01158885

Therapeutic Advances in Childhood Leukemia ConsortiumLeukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Minimal Residual Disease

Start: 2010-08-31End: 2012-10-24Updated: 2021-10-26

Related Papers

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Cancers2024-01-248 citations

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Blood2014-12-063 citations